A maker of cardiac and vascular medical devices and preserved human tissues, Artivion helps surgeons treat aortic disease with products like the On-X mechanical heart valve, BioGlue surgical sealant, and aortic stent grafts, while its cryopreservation service banks donated heart valves and blood vessels. It began in 1984 as CryoLife, founded by Steven Anderson and Robert McNally as the first company to specialize in freezing human heart valves. In 2022 it renamed itself Artivion, a blend of "aorta," "innovation," and "vision."
Artivion borrows $150M to acquire Endospan, swinging to an operating loss as transaction costs and Ascyrus charges hit Q2.
The Endospan acquisition closed, and the bill came due. rose 11% to $125.8 million on continued aortic stent graft and On-X valve growth, but a $19.7 million hit from acquisition costs and an Ascyrus fair-value charge pushed the company to an $8.4 million operating loss. The company is now larger and more leveraged, with $370 million in debt, betting that the NEXUS device will generate returns before the added becomes a drag.
Key takeaways
rose 11% to $125.8 million, driven by a 16% increase in aortic stent grafts and a 19% increase in On-X mechanical heart valves, while surgical sealants were flat.
The company swung to an $8.4 million operating loss from an $8.4 million profit a year ago, as general and administrative expenses rose 38% to $79.8 million, including $11.7 million in Endospan acquisition transaction costs and an $8.0 million non-cash loss from the Ascyrus .
Section summaries
Management's Discussion and Analysis
Q2 FY2026 revenue rose 11% to $125.8M driven by aortic stent grafts and On-X, while Endospan acquisition costs widened operating loss.
⌄
Total revenues grew 11% to $125.8M in Q2 FY2026, led by aortic stent grafts (+16%) and On-X products (+19%), while surgical sealants were flat.
growth was 9% , with EMEA and North America driving aortic stent graft gains and AMDS adoption accelerating after FDA approval.
narrowed 0.7 points to 64.0%, as a 10% increase in gross margin dollars was offset by an unfavorable geographic mix and higher product costs.
The company borrowed $150 million under a delayed-draw term loan to fund the Endospan acquisition, ending the quarter with $370 million in total debt and $77.3 million in cash.
After the quarter closed, a $25 million contingent payment was made upon FDA approval of the AMDS PMA, with up to $75 million in additional sales milestones remaining.
was a $1.3 million use of cash, and was negative $12.0 million, as the acquisition costs and movements consumed cash.
What changed
The Endospan acquisition option, flagged in every prior filing, was exercised in May 2026 with a $150 million borrowing, transforming the balance sheet and adding a new product line, the NEXUS device, to the aortic stent graft .
The 21% aortic stent graft growth rate from Q1 2026 decelerated to 16% in Q2 2026, suggesting the initial AMDS launch stocking phase is beginning to lap, as was flagged as a watch item last quarter.
The 23% preservation services rebound in Q1 2026 did not repeat; the filing does not break out the 's Q2 growth rate, but the narrative focus shifted entirely to the Endospan acquisition and its costs.
The Ascyrus swung to an $8.0 million non-cash loss in Q2 2026, after a $1.7 million loss in Q1 2026, showing these fair-value adjustments continue to swing unpredictably, a risk flagged since FY2023.
What to watch
Whether the $150 million Endospan borrowing and the additional $25 million AMDS milestone payment push and ratios to levels that consume the generated by the base business in Q3 2026.
How quickly Endospan's NEXUS contributes to the top line and whether it can offset the deceleration in aortic stent graft growth as the company laps the strongest AMDS launch quarters from 2025.
Whether the Ascyrus fair-value adjustments continue to produce large non-cash swings in operating expenses, or whether the Q2 2026 charge represents a catch-up adjustment that will not repeat at the same magnitude.
Any update from the FDA on the tuberculosis risk draft guidances for tissue processing, which the risk factors warn could materially constrain the Preservation Services 's tissue supply.
dollars rose 10% but margin rate dipped to 64% from 65% due to unfavorable geographic mix and higher product costs.
Operating expenses surged, with general and administrative costs up 38% to $79.8M, including $11.7M in Endospan acquisition transaction costs and an $8.0M Ascyrus loss.
The company borrowed $150M under a new delayed draw term loan to fund the Endospan acquisition, ending Q2 with $370M in total debt and $77.3M in cash.
Post-quarter, a $25M contingent payment was made upon FDA approval of the AMDS PMA, with up to $75M in additional sales milestones remaining.
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to a variety of market risks, including the effects of changes in interest rates (including credit spreads) and foreign currency exchange rates. We manage our exposure to these market risks through our regular operating and financing activities. As of June 30, 202…
⌄
We are exposed to a variety of market risks, including the effects of changes in interest rates (including credit spreads) and foreign currency exchange rates. We manage our exposure to these market risks through our regular operating and financing activities. As of June 30, 2026 there has been no material change in the information reported under Part II, Item 7A – “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2025.
From time to time, we are involved in legal proceedings concerning matters arising from the conduct of our business activities. We regularly evaluate the status of legal proceedings in which we are involved in order to assess whether a loss is probable or whether there is a reas…
⌄
From time to time, we are involved in legal proceedings concerning matters arising from the conduct of our business activities. We regularly evaluate the status of legal proceedings in which we are involved in order to assess whether a loss is probable or whether there is a reasonable possibility that a loss or additional loss may have been incurred and to determine if accruals are appropriate. We further evaluate each legal proceeding to assess whether an estimate of possible loss or range of loss can be made.
Based on current knowledge, we do not believe that there are any pending matters that could potentially have a material, adverse effect on our business, financial condition, results of operations, or cash flows. We are, however, engaged in various legal actions in the normal course of business. There can be no assurances in light of the inherent uncertainties involved in any potential legal proceedings, some of which are beyond our control, and an adverse outcome in any legal proceeding could be material to our results of operations or cash flows for any particular reporting period.
Key risks include international regulatory/payback exposure, tissue supply regulation, single-source dependency, and integration of the Endospan acquisition.
⌄
International operations expose the company to foreign currency fluctuations, inflationary pressures, and complex compliance obligations, including a potential $2.3M repayment to Italy for medical device overpayments.
Proposed FDA on tuberculosis risk in donated tissue could significantly reduce the supply of safe implantable human tissue, threatening a major source.
The business is heavily dependent on single and sole-source suppliers for critical components like BioGlue delivery devices and On-X valve parts, with past disruptions leading to product line abandonment.
The recent acquisition of Endospan introduces new risks, including reliance on a single manufacturing facility in Herzliya, Israel, amid regional conflict, and the challenge of driving adoption for the NEXUS product family.
A cybersecurity incident in late 2024 disrupted global ERP systems and operations, and the company continues to incur expenses to improve its infrastructure and security posture.
Regulatory transitions, particularly the EU's Medical Device Regulation (MDR), create uncertainty and potential delays for maintaining CE Marks and commercializing new products in Europe.